Johnson & Johnson expects to fall far short of its commitment to deliver 10 million doses of its COVID-19 vaccine by the end of February, with under 4 million to be ready to ship after a hoped-for emergency use authorization from the FDA. The disclosure of the shortfall by Johnson & Johnson is the first public measure of exactly how far the drug company has fallen behind its production goals.